General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress | globenewswire.com • |
Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today? | investorplace.com • |
Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today? | investorplace.com • |
Hot Penny Stocks to Buy This Week? 3 to Watch Now | pennystocks.com • |
Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference | globenewswire.com • |
3 High Volume Penny Stocks To Watch Before Next Week | pennystocks.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-01-03 | 2023-09 | 0 | N/A | N/A | N/A |
2023-10-03 | 2023-06 | 0 | N/A | N/A | N/A |
2023-07-04 | 2023-03 | 0 | N/A | N/A | N/A |
2023-03-31 | 2022-12 | 0 | N/A | N/A | N/A |
2022-11-09 | 2022-09 | -0.42 | N/A | N/A | N/A |
2022-08-09 | 2022-06 | -0.52 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-09-13 | Guggenheim | Downgrade | Buy | Neutral |
2022-09-09 | Morgan Stanley | Upgrade | Equal-Weight | |
2022-08-09 | SVB Leerink | Upgrade | Market Perform | |
2022-05-11 | Morgan Stanley | Upgrade | Equal-Weight | |
2022-05-11 | HC Wainwright & Co. | Upgrade | Buy | |
2022-05-10 | SVB Leerink | Upgrade | Market Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-02-23 | APPELHANS DANNIELLE | Chief Executive Officer | 0.00 | Sale |
2023-01-31 | CAGNONI PABLO J | Director | 66.08K | Sale |
2019-12-15 | CARPENTER CHRISTOPHER L | Officer | 34.84K | Sale |
2020-04-21 | COUGHLIN CHRISTINA M M.D., PH.D. | Officer | 19.00K | Purchase |
2022-04-20 | EPSTEIN DAVID R | Director | 4.72M | Purchase |
2021-03-18 | FLAGSHIP VENTURES FUND IV GENERAL PARTNER L L C | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | Flagship Pioneering Inc. | 38.51M | 3.20M | 42.60% |
2022-12-30 | FMR, LLC | 12.38M | 1.03M | 13.69% |
2022-12-30 | Baillie Gifford and Company | 4.87M | 404.14K | 5.39% |
2022-12-30 | Artal Group S.A. | 2.04M | 169.54K | 2.26% |
2022-12-30 | Vanguard Group, Inc. (The) | 1.68M | 139.16K | 1.85% |
2022-12-30 | Acadian Asset Management. LLC | 1.28M | 106.01K | 1.41% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-11-29 | Fidelity Growth Company Fund | 4.39M | 364.29K | 4.86% |
2022-11-29 | Fidelity Growth Company K6 Fund | 1.34M | 110.91K | 1.48% |
2022-11-29 | Fidelity Series Growth Company Fund | 1.11M | 91.91K | 1.23% |
2022-09-29 | Vanguard Total Stock Market Index Fund | 1.07M | 88.55K | 1.18% |
2022-09-29 | Vanguard Extended Market Index Fund | 553.39K | 45.93K | 0.61% |
2022-11-29 | Fidelity Extended Market Index Fund | 225.43K | 18.71K | 0.25% |
What’s Gordon Gecko’s (Michael Douglas’) famous line: “it’s like a dog with fleas.” We can only hope for good news at this point.
Ruby# are they still presenting at ASCO?
I love you..
Ruby... good article in stat today
Rate your confidence [1 - 10] - low to high - that Ruby hits 17 in next 30 days or more...
What is happening